This is a preview of subscription content, log in via an institution to check access.
Notes
see Reactions 1742 p6; 803377653
References
Health Canada. Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR) Internet Document : 15 Mar 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69336a-eng.php
European Medicines Agency (EMA). Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis. Internet Document : 20 Mar 2019. Available from: URL: https://www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis
Rights and permissions
About this article
Cite this article
Risk of pulmonary embolism with high-dose tofacitinib. Reactions Weekly 1746, 4 (2019). https://doi.org/10.1007/s40278-019-59442-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-59442-7